ImmunityBio, Inc. (IBRX) Cash Flow Statement
ImmunityBio, Inc. (IBRX) generated -$281.1M of operating cash flow over the twelve months to 2026-06-30, spent $7.4M on capital expenditure and had free cash flow of -$288.5M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
IBRXImmunityBio, Inc.Follow IBRX — free
—
Price chart with a free account
- Market cap
- 8.7B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
| Line | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -25.3 | -38.6 | -48.8 | -63.4 | -152.1 | -171.7 | -274.4 | -337.5 | -366.8 | -391.2 | -304.9 | -281.1 | |
| Capital expenditure | 2.2 | 6.6 | 34.8 | 13.1 | 4.3 | 1.7 | 33.6 | 78.2 | 30.6 | 6.9 | 4.3 | -7.4 | |
| Free cash flow | -27.5 | -45.2 | -83.6 | -76.5 | -156.4 | -173.4 | -308.0 | -415.7 | -397.3 | -398.1 | -309.2 | -288.5 | |
| Share repurchases | 4.8 | 15.8 | 15.2 | 0.2 | 2.5 | 0.0 | 0.0 | — | — | — | — | — | |
| Stock-based compensation | 211.2 | 73.9 | 37.0 | 23.4 | 3.4 | 2.2 | 57.2 | 40.2 | 49.2 | 34.4 | 36.8 | — |
USD millions · SEC XBRL
ImmunityBio, Inc. — questions
- What is ImmunityBio, Inc.'s operating cash flow?
- -$281.1M over the twelve months to 2026-06-30.
- How much does ImmunityBio, Inc. spend on capital expenditure?
- $7.4M over the twelve months to 2026-06-30.
- What is ImmunityBio, Inc.'s free cash flow?
- -$288.5M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from ImmunityBio, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.